EUCRAF Workshop Icon

Immunogenicity Part 1 » Participants
Annual Meeting eucraf eucraf eucraf eucraf eucraf


The goal of the 1st part of the workshop was to illustrate the way in which specialist knowledge from different drug development disciplines may be effectively integrated to identify, evaluate and mitigate risks associated with undesirable immunogenicity of therapeutic proteins and peptides.


Companies, institutions

Ablynx IBR Inc. PreClinical Safety (PCS) Consultants Ltd
Agennix AG InflaRx GmbH Sandoz / Hexal
Baxter Innovations GmbH

Laboratorios De Especialidades

Immunologicas S.A De C.V

SuppreMol GmbH
Boehringer Ingelheim Pharma GmbH & Co KG  MAB Discovery GmbH Swissmedic
BSL BIOSERVICE Scientific Laboratories GmbH Medical Products Agency synlab Services GmbH
CSL Behring GmbH Merck KGaA Takeda
Dr. Regenold GmbH Merckle GmbH Two Hats Regulatory Science GbR
Drug Development Licensing Limited NDA Regulatory Service GmbH. UCB Celltech
F. Hoffmann-La Roche Ltd Novozymes  University of Regensburg


Assessor / Inspector Group Leader Immunoanalytics Scientist
Assessor, Dept. Of Pharmaceutics and Biotechnology Head DRA CMC Scientist Antibody Technologies
Associate Director Head of Business Development Senior Assoicate

Board Certified Expert in Pharmacology and Toxicology,

Managing Director

Laboratory Head Senior Consultant
Chief Medical Officer Manager of Projects and Technical assistance Senior Manager Regulatory Affairs
Clinical and Regulatory Consultant Manager Regulatory Affairs Biosimilars Senior Medical Advisor
Consultant Product Manager Senior RA Biosimilars
Director Non-Clinical Development Regulatory Affairs Manager Student Master Chemie
Director Protein Science Regulatory Scientist
Expert Scientist Research Scientist


Austria Germany Switzeland
Belgium Mexico United Kingdom
Denmark     Sweden